Artículos por temáticas

Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease

Arora D, Bhatt S, Kumar M, Vattikonda HDC, Taneja Y, Jain V, Joshi V, Gali CC.

Curr Pharm Des. 2020;26(27):3281-3299. doi: 10.2174/1381612826666200331085854.

[Current Clinical Trials in the Treatment of Alzheimer's Disease]

Tamaoka A.

Brain Nerve. 2020 Jan;72(1):23-34. doi: 10.11477/mf.1416201475.

"What Doesn't Kill You Makes You Stronger": Future Applications of Amyloid Aggregates in Biomedicine

Abdelrahman S, Alghrably M, Lachowicz JI, Emwas AH, Hauser CAE, Jaremko M.

Molecules. 2020 Nov 11;25(22):5245. doi: 10.3390/molecules25225245.

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, Russu A, Janssens L, Tesseur I, Tritsmans L, Van Nueten L, Engelborghs S.

Alzheimers Res Ther. 2020 May 14;12(1):58. doi: 10.1186/s13195-020-00614-5.

Testing whether the progression of Alzheimer's disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data

Zhang N, Zheng X, Liu H, Zheng Q, Li L.

Alzheimers Res Ther. 2020 May 26;12(1):64. doi: 10.1186/s13195-020-00630-5.

Undiscovered Roles for Transthyretin: From a Transporter Protein to a New Therapeutic Target for Alzheimer's Disease

Gião T, Saavedra J, Cotrina E, Quintana J, Llop J, Arsequell G, Cardoso I.

Int J Mol Sci. 2020 Mar 18;21(6):2075. doi: 10.3390/ijms21062075.

One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults

Martinez AI, Abner EL, Jicha GA, Rigsby DN, Eckmann LC, Huffmyer MJ, Moga DC.

J Manag Care Spec Pharm. 2020 Apr;26(4):520-528. doi: 10.18553/jmcp.2020.26.4.520.

An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease

Chamberlain S, Gabriel H, Strittmatter W, Didsbury J.

J Alzheimers Dis. 2020;73(3):1085-1103. doi: 10.3233/JAD-190864.

[Research progress in pharmacological effects of Erigeron breviscapus and its active ingredients for treatment of Alzheimer's disease]

Pu YZ, Su C.

Zhongguo Zhong Yao Za Zhi. 2020 Dec;45(23):5650-5657. doi: 10.19540/j.cnki.cjcmm.20200717.602.

Time for Well-Powered Controlled Prospective Studies to Test a Causal Role for Herpes Viruses in Alzheimer's Disease Using Antiherpetic Drugs

Goldschmidt-Clermont PJ, Volinsky FG, LaRosa SP, Gilbert JR, Periçak-Vance MA.

J Gerontol A Biol Sci Med Sci. 2020 May 22;75(6):1058-1060. doi: 10.1093/gerona/glz150.

Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial

Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D.

Alzheimers Dement. 2020 Mar;16(3):541-551. doi: 10.1002/alz.12035. Epub 2020 Jan 15.

Comparative pharmacokinetic study of the components in Alpinia oxyphylla Miq.-Schisandra chinensis (Turcz.) Baill. herb pair and its single herb between normal and Alzheimer's disease rats by UPLC-MS/MS

Qi Y, Cheng X, Jing H, Yan T, Xiao F, Wu B, Bi K, Jia Y.

J Pharm Biomed Anal. 2020 Jan 5;177:112874. doi: 10.1016/j.jpba.2019.112874. Epub 2019 Sep 12.

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S.

J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134.

Tau Protein Aggregation in Alzheimer's Disease: Recent Advances in the Development of Novel Therapeutic Agents

Monteiro KLC, Alcântara MGDS, de Aquino TM, da Silva-Júnior EF.

Curr Pharm Des. 2020;26(15):1682-1692. doi: 10.2174/1381612826666200414164038.

The potential role of nanoyttria in alleviating oxidative stress biomarkers: Implications for Alzheimer's disease therapy

Tang KS.

Life Sci. 2020 Oct 15;259:118287. doi: 10.1016/j.lfs.2020.118287. Epub 2020 Aug 16.